1. Home
  2. GGR vs QTTB Comparison

GGR vs QTTB Comparison

Compare GGR & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gogoro Inc.

GGR

Gogoro Inc.

N/A

Current Price

$3.43

Market Cap

47.7M

ML Signal

N/A

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

HOLD

Current Price

$5.90

Market Cap

44.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGR
QTTB
Founded
2011
2015
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.7M
44.3M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
GGR
QTTB
Price
$3.43
$5.90
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
16.2K
289.6K
Earning Date
05-07-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
136.78
EPS
N/A
2.42
Revenue
N/A
$53,737,000.00
Revenue This Year
$5.07
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$3.00
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$1.38
52 Week High
$6.21
$8.05

Technical Indicators

Market Signals
Indicator
GGR
QTTB
Relative Strength Index (RSI) 49.06 49.96
Support Level $3.20 $5.51
Resistance Level $3.55 $6.37
Average True Range (ATR) 0.17 0.98
MACD -0.04 -0.04
Stochastic Oscillator 20.29 16.37

Price Performance

Historical Comparison
GGR
QTTB

About GGR Gogoro Inc.

Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.

Share on Social Networks: